A review of antioxidants and Alzheimer's disease

Annals of Clinical Psychiatry

Volumn 17, Issue 4, 2005, Pages 269-286

  Frank, Bradford ^a,b   Gupta, Sanjay ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b NONE   (United States)

Author keywords

Alzheimer's; Anti oxidants; Antioxidants; Dementia; Neurodegenerative

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CURCUMIN; GINKGO BILOBA EXTRACT; HUPERZINE A; LEVACECARNINE; MELATONIN; RETINOL; THIOCTIC ACID;

ALZHEIMER DISEASE; BACOPA MONNIERI; CLINICAL TRIAL; COGNITION; DATA BASE; DRUG DOSE REGIMEN; DRUG RESEARCH; DRUG SAFETY; GINKGO BILOBA; HUMAN; LIBRARY; META ANALYSIS; NEUROPROTECTION; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ACETYLCARNITINE; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIOXIDANTS; ASCORBIC ACID; BRAIN; COUMARIC ACIDS; GINKGO BILOBA; HUMANS; LIPID PEROXIDATION; MELATONIN; NERVE DEGENERATION; OXIDATIVE STRESS; PANAX; PHYTOTHERAPY; THIOCTIC ACID; VITAMIN E;

EID: 28844462038     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: 10.1080/10401230500296428     Document Type: Review

References (187)

1. Youdim KA, Joseph JA: A possible emerging role of phytochemicals in improving age-related neurological dysfunctions: A multiplicity of effects. Free Radic Biol Med 2001; 30:583-594
2. Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC: Cache County Study Investigators. Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Arch Gen Psychiatry 2004; 61:518-524
3. Tschanz JT, Corcoran C, Skoog I, Khachaturian AS, Herrick J, Hayden KM, Welsh-Bohmer KA, Calvert T, Norton MC, Zandi P, Breitner JC: Cache County Study Group. Dementia: The leading predictor of death in a defined elderly population: The Cache County Study. Neurology 2004; 62:1156-1162
4. Doraiswamy PM: Non-cholinergic strategies for treating and preventing AD. CNS Drugs 2002; 12:811-824
5. McLellan ME, Kajdasz ST, Hyman BT, Bacskai BJ: In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J Neurosci 2003; 23:2212-2217
6. Prasad KN, Cole WC, Prasad KC: Risk factors for AD: Role of multiple antioxidants, non-steroidal anti-inflammatory and cholinergic agents alone or in combination in prevention and treatment. J Am Coll Nutr 2002; 21:506-522
7. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, Stijnen T, Hofman A, Witteman JC, Breteler MM: Inflammatory proteins in plasma and the risk of dementia: The Rotterdam Study. Arch Neurol 2004; 61:668-672
8. Cornett CR, Markesbery WR, Ehmann WD: Imbalances of trace elements related to oxidative damage in AD brain. Neurotoxicol 1998; 19:339-345
9. Casadesus G, Smith MA, Zhu X, Aliev G, Cash AD, Honda K, Petersen RB, Perry G: Alzheimer disease: Evidence for a central pathogenic role of iron-mediated reactive oxygen species. J Alzheimers Dis. 2004; 6:165-169
10. Mandel S, Weinreb O, Amit T, Youdim MB: Cell signaling pathways in the neuroprotective actions of the green tea polyphenols (-)-epigallocatechin-3- gallate: Implications for neurodegenerative diseases. J Neurochem 2004; 88:1555-1569
11. Ong WY, Halliwell B: Iron, atherosclerosis, and neurodegeneration: A key role for cholesterol in promoting iron-dependent oxidative damage?. Ann N Y Acad Sci 2004; 1012:51-64
12. Ong WY, Tan B, Pan N, Jenner A, Whiteman M, Ong CN, Watt F, Halliwell B: Increased iron staining in the cerebral cortex of cholesterol fed rabbits. Mech Ageing Dev 2004; 125:305-313
13. Dwyer BE, Raina AK, Perry G, Smith MA: Homocysteine and AD: A modifiable risk?. Free Radic Biol Med 2004; 36:1471-1475
14. Kannan K, Jain SK: Oxidative stress and apoptosis. Pathophysiology 2000; 7:153-163
15. Ho PI, Collins SC, Dhitavat S, Ortiz D, Ashline D, Rogers E, Shea TB: Homocysteine potentiates beta-amyloid neurotoxicity: Role of oxidative stress. J Neurochem 2001; 78:249-253
16. Calabrese V, Scapagnini G, Colombrita C, Ravagna A, Pennisi G, Giuffrida Stella AM, Galli F, Butterfield DA: Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: A nutritional approach. Amino Acids 2003; 25:437-444
17. Cadenas E, Davies KJ: Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 2000; 29:222-230
18. Hinerfeld D, Traini MD, Weinberger RP, Cochran B, Doctrow SR, Harry J, Melov S: Endogenous mitochondrial oxidative stress: Neuodegeneration, proteomic analysis, specific respiratory chain defects, and efficacious antioxidant therapy in superoxide dismutase 2 null mice. J Neurochem 2004; 88:657-667
19. Kumar U, Dunlop DM, Richardson JS: Mitochondria from Alzheimer's fibroblasts show decreased uptake of calcium and increased sensitivity to free radicals. Life Sci 1994; 54:1855-1860
20. Marlatt M, Lee HG, Perry G, Smith MA, Zhu X: Sources and mechanisms of cytoplasmic oxidative damage in AD. Acta Neurobiol Exp (Wars) 2004; 64:81-87
21. Smith MA, Nunomura A, Zhu X, Takeda A, Perry G: Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxid Redox Signal 2000; 2:413-420
22. Romero FJ, Bosch-Morell F, Romero MJ, Jareno EJ, Romero B, Marin N, Roma J: Lipid peroxidation products and antioxidants in human disease. Environ Health Perspect 1998; Suppl 5:1229-1234
23. Cecchi C, Fiorillo C, Sorbi S, Latorraca S, Nacmias B, Bagnoli S, Nassi P, Liguri G: Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients. Free Radic Biol Med 2002; 33:1372-1379
24. Prasad KN, Hovland AR, Cole WC, Prasad KC, Nahreini P, Edwards-Prasad J, Andreatta CP: Multiple antioxidants in the prevention and treatment of Alzheimer disease: analysis of biologic rationale. Clin Neuropharmacol 2000; 23:2-13
25. Russo A, Borrelli F, Campisi A, Acquaviva R, Raciti G, Vanell A: Nitric oxide-related toxicity in cultured astrocytes: Effect of Bacopa monniera. Life Sci 2003; 73:1517-1526
26. Metodiewa D, Koska C: Reactive oxygen species and reactive nitrogen species: Relevance to cyto (neuro)toxic events and neurologic disorders. An overview. Neurotoxi Res 2000; 1:197-233
27. Gracy RW, Talent JM, Kong Y, Conrad CC: Reactive oxygen species: The unavoidable environmental insult?. Mutat Res 1999; 428:17-22
28. Hensley K, Floyd RA: Reactive oxygen species and protein oxidation in aging: A look back, a look ahead. Arch Biochem Biophys 2002; 397:377-383
29. Gilgun-Sherki Y, Melamed E, Offen D: Antioxidant treatment in AD: Current state. J Mol Neurosci 2003; 1:1-12
30. Di Matteo V, Esposito E: Biochemical and therapeutic effects of antioxidants in the treatment of AD, Parkinson's disease, and amyotrophic lateral sclerosis. Curr Drug Targets CNS Neurol Disord 2003; 2:95-107
31. Varadarajan S, Yatin S, Aksenova M, Butterfield DA: Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 2000; 130:184-208
32. Rutten BP, Steinbusch HW, Korr H, Schmitz C: Antioxidants and AD: From bench to bedside (and back again). Curr Opin Clin Nutr Metab Care 2002; 5:645-651
33. Melo JB, Agostinho P, Oliveira CR: Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta-peptide. Neurosci Res 2003; 45:117-127
34. Grundman M: Delaney P: Antioxidant strategies for AD. Proc Nutr Soc 2002; 61:191-202
35. Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC, Breteler MM: Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002; 287:3223-3229
36. Luchsinger JA, Tang MX, Shea S, Mayeux R: Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003; 60:203-208
37. Laurin D, Masaki KH, Foley DJ, White LR, Launer LJ: Midlife dietary intake of antioxidants and risk of late-life incident dementia: The Honolulu-Asia Aging Study. Am J Epidemiol 2004; 159:959-967
38. Repetto MG, Reides CG, Evelson P, Kohan S, de Lustig ES, Llesuy SF: Peripheral markers of oxidative stress in probable Alzheimer patients. Eur J Clin Invest 1999; 29:643-649
39. Perkins AJ, Hendrie HC, Callahan CM, Gao S, Unverzagt FW, Xu Y, Hall KS, Hui SL: Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. Am J Epidemiol 1999; 150:37
40. Polidori MC, Mecocci P: Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease. J Alzheimers Dis 2002; 4:517-522
41. Foy CJ, Passmore AP, Vahidassr MD, Young IS, Lawson JT: Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease. QJM 1999; 92:39-45
42. Sinclair AJ, Bayer AJ, Johnston J, Warner C, Maxwell SR: Altered plasma antioxidant status in subjects with AD and vascular dementia. Int J Geriatr Psychiatry 1998; 1312:840-845
43. Mecocci P: Oxidative stress in mild cognitive impairment and AD: A continuum. J Alzheimers Dis 2004; 6:159-163
44. Rinaldi P, Polidori MC, Metastasio A, Marini E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecocci P: Plasma antioxidants are similarly depleted in mild cognitive impairment and in AD. Neurobiol Aging 2003; 24:915-919
45. Mendoza-Nunez VM, Sanchez-Rodriguez MA, Retana-Ugalde R, Vargas-Guadarrama LA, Altamirano-Lozano MA: Total antioxidant levels, gender, and age as risk factors for DNA damage in lymphocytes of the elderly. Mech Ageing Dev 2001; 122:835-847
46. Vina J, Sastre J, Pallardo F, Borras C: Mitochondrial theory of aging: importance to explain why females live longer than males. Antioxid Redox Signal 2003; 5:549-556
47. Pettegrew JW, Levine J, McClure RJ: Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in AD and geriatric depression. Mol Psychiatry 2000; 5:616-632
48. No author sited: Acetyl-L-carnitine. Altern Med Rev 1999; 4:438-441
49. Dhitavat S, Ortiz D, Shea TB, Rivera ER: Acetyl-L-carnitine protects against amyloid-beta neurotoxicity: Roles of oxidative buffering and ATP levels. Neurochem Res 2002; 27:501-505
50. Virmani MA, Caso V, Spadoni A, Rossi S, Russo F, Gaetani F: The action of acetyl-L-carnitine on the neurotoxicity evoked by amyloid fragments and peroxide on primary rat cortical neurones. Ann N Y Acad Sci 2001; 939:162-178
51. Ando S, Kobayashi S, Waki H, Kon K, Fukui F, Tadenuma T, Iwamoto M, Takeda Y, Izumiyama N, Watanabe K, Nakamura H: Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carnitine. J Neurosci Res 2002; 703:519-527
52. Brooks JO 3rd, Yesavage JA, Carta A, Bravi D: Acetyl L-carnitine slows decline in younger patients with AD: A reanalysis of a double-blind, placebo-controlled study using the trilinear approach. Int Psychogeriatr 1998; 10:193-203
53. Montgomery SA, Thal LJ, Amrein R: Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild AD. Int Clin Psychopharmacol 2003; 18:61-71
54. Hudson S, Tabet N: Acetyl-L-carnitine for dementia. Cochrane Database Syst Rev 2003; CD003158
55. Thal LJ, Calvani M, Amato A, Carta A: A 1-year controlled trial of acetyl-1-carnitine in early-onset AD. Neurology 2000; 55:805-810
56. Bianchetti A, Rozzini R, Trabucchi M: Effects of acetyl-L-carnitine in AD patients unresponsive to acetylcholinesterase inhibitors. Curr Med Res Opin 2003; 19:350-353
57. Ichikawa M, Ryu K, Yoshida J, Ide N, Yoshida S, Sasaoka T, Sumi S: Antioxidant effects of tetrahydro-beta-carboline derivatives identified in aged garlic extract. Biofactors 2002; 16:57-72
58. Ishige K, Schubert D, Sagara Y: Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic Biol Med 2001; 30:433-446
59. Borek C: Antioxidant health effects of aged garlic extract. J Nutr 2001; 131:1010S-5S
60. Jackson R, McNeil B, Taylor C, Holl G, Ruff D, Gwebu ET: Effect of aged garlic extract on caspase-3 activity, in vitro. Nutr Neurosci 2002; 5:287-290
61. Peng Q, Buz'Zard AR, Lau BH: Neuroprotective effect of garlic compounds in amyloid-beta peptide-induced apoptosis in vitro. Med Sci Monit 2002; 8:BR328-337
62. Sumi S, Tsuneyoshi T, Matsuo H, Yoshimatsu T: Isolation and characterization of the genes up-regulated in isolated neurons by aged garlic extract (AGE). J Nutr 2001; 131:1096S-1099S
63. Nishiyama N, Moriguchi T, Morihara N, Saito H: Ameliorative effect of S-allylcysteine, a major thioallyl constituent in aged garlic extract, on learning deficits in senescence-accelerated mice. J Nutr 2001; 131:1093S-1095S
64. Zhang L, Xing GQ, Barker JL, Chang Y, Maric D, Ma W, Li BS, Rubinow DR: Alpha-lipoic acid protects rat cortical neurons against cell death induced by amyloid and hydrogen peroxide through the Akt signalling pathway. Neurosci Lett 2001; 312:125-128
65. Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, Butterfield DA, Morley JE: The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem 2003; 84:1173-1183
66. Sharma M, Gupta YK: Effect of alpha lipoic acid on intracerebroventricular streptozotocin model of cognitive impairment in rats. Eur Neuropsychopharmacol 2003; 13:241-247
67. Arivazhagan P, Panneerselvam C: Neurochemical changes related to ageing in the rat brain and the effect of DL-alpha-lipoic acid. Exp Gerontol 2002; 37:1489-1494
68. Liu J, Head E, Gharib AM, Yuan W, Ingersoll RT, Hagen TM, Cotman CW, Ames BN: Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: Partial reversal by feeding acetyl-L-carnitine and/or R-alpha-lipoic acid. Proc Natl Acad Sci USA 2002; 99:2356-2361
69. Hager K, Marahrens A, Kenklies M, Riederer P, Munch G: Alpha-lipoic acid as a new treatment option for Azheimer type dementia. Arch Gerontol Geriatr 2001; 32:275-282
70. Lovell MA, Xie C, Xiong S, Markesbery WR: Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid. J Alzheimers Dis 2003; 5:229-239
71. Sauer J, Tabet N, Howard R: Alpha lipoic acid for dementia. Cochrane Database Syst Rev 2004; CD004244
72. Rai D, Bhatia G, Palit G, Pal R, Singh S, Singh HK: Adaptogenic effect of Bacopa monniera (Brahmi). Pharmacol Biochem Behav 2003; 75:823-830
73. Das A, Shanker G, Nath C, Pal R, Singh S, Singh H: A comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba: Anticholinesterase and cognitive enhancing activities. Pharmacol Biochem Behav 2002; 73:893-900
74. Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S: Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampus. Phytother Res 2000; 14:174-179
75. Russo A, Borrelli F, Campisi A, Acquaviva R, Raciti G, Vanell A: Nitric oxide-related toxicity in cultured astrocytes: Effect of Bacopa monniera. Life Sci 2003; 73:1517-1526
76. Nathan PJ, Tanner S, Lloyd J, Harrison B, Curran L, Oliver C, Stough C: Effects of a combined extract of Ginkgo biloba and Bacopa monniera on cognitive function in healthy humans. Hum Psychopharmacol 2004; 19:91-96
77. Shults CW: Coenzyme Q10 in neurodegenerative diseases. Curr Med Chem 2003; 10:1917-1921
78. Beal MF: Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci 2003; 991:120-131
79. Lankin VZ, Tikhaze AK, Kukharchuk VV, Konovalova GG, Pisarenko OI, Kaminnyi AI, Shumaev KB, Belenkov YN: Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins. Mol Cell Biochem 2003; 249:129-140
80. Miquel J, Bernd A, Sempere JM, Diaz-Alperi J, Ramirez A: The curcuma antioxidants: Pharmacological effects and prospects for future clinical use. A review. Arch Gerontol Geriatr 2002; 34:37-46
81. Ono K, Hasegawa K, Naiki H, Yamada M: Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 2004; 75:742-750
82. Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, Cole GM: Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 2001; 6:993-1005
83. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM: The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001; 21:8370-8377
84. Chainani-Wu N: Safety and anti-inflammatory activity of curcumin: A component of tumeric (Curcuma longa). J Altern Complement Med 2003; 9:161-168
85. Trombino S, Serini S, Di Nicuolo F, Celleno L, Ando S, Picci N, Calviello G, Palozza P: Antioxidant effect of ferulic acid in isolated membranes and intact cells: Synergistic interactions with alpha-tocopherol, beta-carotene, and ascorbic acid. J Agric Food Chem 2004; 528:2411-2420
86. Clostre F: Ginkgo biloba extract (EGb 761). State of knowledge in the dawn of the year 2000. Ann Pharm Fr 1999; Suppl 1:1S8-88
87. DeFeudis FV, Drieu K: Ginkgo biloba extract (EGb 761) and CNS functions: Basic studies and clinical applications. Curr Drug Targets 2000; 1:25-58
88. McKenna DJ, Jones K, Hughes K: Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med 2001; 7:70-86, 88-90
89. Yoshikawa T, Naito Y, Kondo M: Ginkgo biloba leaf extract: Review of biological actions and clinical applications. Antioxid Redox Signal 1999; 1:469-480
90. Christen Y, Maixent JM: What is Ginkgo biloba extract EGb 761? An overview - from molecular biology to clinical medicine. Cell Mol Biol 2002; 48:601-611
91. Smith JV, Luo Y: Studies on molecular mechanisms of Ginkgo biloba extract. Appl Microbiol Biotechnol 2004; 64:465-472
92. Zimmermann M, Colciaghi F, Cattabeni F, Di Luca M: Ginkgo biloba extract: From molecular mechanisms to the treatment of Alzhelmer's disease. Cell Mol Biol (Noisy-le-grand) 2002; 48:613-623
93. Gertz HJ, Kiefer M: Review about Ginkgo biloba special extract EGb 761 (Ginkgo). Curr Pharm Des 2004; 10:261-264
94. Kanowski S, Hoerr R: Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry 2003; 36:297-303
95. Mix JA, Crews WD Jr: A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: Neuropsychological findings. Hum Psychopharmacol 2002; 17:267-277
96. Birks J, Grimley EV, Van Dongen M: Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2002; CD003120
97. van Dongen MC, van Rossum E, Kessels AG, Sielhorst HJ: Knipschild PG: The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: New results of a randomized clinical trial. J Am Geriatr Soc 2000; 48:1183-1194
98. van Dongen M, van Rossum E, Kessels A, Sielhorst H, Knipschild P: Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Clin Epidemiol 2003; 56:367-376
99. Colciaghi F, Borroni B, Zimmermann M, Bellone C, Longhi A, Padovani A, Cattabeni F, Christen Y, Di Luca M: Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiol Dis 2004; 16:454-460
100. Tang F, Nag S, Shiu SY, Pang SF: The effects of melatonin and Ginkgo biloba extract on memory loss and choline acetyltransferase activities in the brain of rats infused intracerebroventricularly with beta-amyloid 1-40. Life Sci 2002; 71:2625-2631
101. Williams B, Watanabe CM, Schultz PG, Rimbach G, Krucker T: Age-related effects of Ginkgo biloba extract on synaptic plasticity and excitability. Neurobiol Aging 2004; 25:955-962
102. Bastianetto S, Quirion R: EGb 761 is a neuroprotective agent against beta-amyloid toxicity. Cell Mol Biol (Noisy-le-grand) 2002; 48:693-697
103. Murphy LL, Lee TJ: Ginseng, sex behavior, and nitric oxide. Ann N Y Acad Sci 2002; 962:372-377
104. Price A, Gazewood J: Korean red ginseng effective for treatment of erectile dysfunction. J Fam Pract 2003; 52:20-21
105. Hong B, Ji YH, Hong JH, Nam KY, Ahn TY: A double-blind crossover study evaluating the efficacy of Korean red ginseng in patients with erectile dysfunction: A preliminary report. J Urol 2002; 5:2070-2073
106. Surh YJ, Lee JY, Choi KJ, Ko SR: Effects of selected ginsenosides on phorbol ester-induced expression of cyclooxygenase-2 and activation of NF-kappaB and ERK1/2 in mouse skin. Ann N Y Acad Sci 2002; 973:396-401
107. Yokozawa T, Satoh A, Cho EJ: Ginsenoside-Rd attenuates oxidative damage related to aging in senescence-accelerated mice. J Pharm Pharmacol 2004; 56:107-113
108. Lee JH, Kim SR, Bae CS, Kim D, Hong H, Nah S: Protective effect of ginsenosides, active ingredients of Panax ginseng, on kainic acid-induced neurotoxicity in rat hippocampus. Neurosci Lett 2002; 325:129-133
109. Jang MH, Chang HK, Shin MC, Lee TH, Kim YP, Kim EH, Kim CJ: Effect of ginseng radix on c-Fos expression in the hippocampus of streptozotocin-induced diabetic rats. J Pharmacol Sci 2003; 91:149-152
110. Coon JT, Ernst E: Panax ginseng: A systematic review of adverse effects and drug interactions. Drug Saf 2002; 25:323-344
111. Siddiqui IA, Afaq F, Adhami VM, Ahmad N, Mukhtar H: Antioxidants of the beverage tea in promotion of human health. Antioxid Redox Signal 2004; 6:571-582
112. Gouni-Berthold I, Sachinidis A: Molecular mechanisms explaining the preventive effects of catechins on the development of proliferative diseases. Curr Pharm Des 2004; 10:1261-1271
113. Jeon SY, Bae K, Seong YH, Song KS: Green tea catechins as a BACE1 (beta-secretase) inhibitor. Bioorg Med Chem Lett 2003; 13:3905-3908
114. Ahmed I, John A, Vijayasarathy C, Robin MA, Raza H: Differential modulation of growth and glutathione metabolism in cultured rat astrocytes by 4-hydroxynonenal and green tea polyphenol, epigallocatechin-3-gallate. Neurotoxicology 2002; 23:289-300
115. Lee SR, Im KJ, Suh SI, Jung JG: Protective effect of green tea polyphenol (-)-epigallocatechin gallate and other antioxidants on lipid peroxidation in gerbil brain homogenates. Phytother Res 2003; 17:206-209
116. Choi YT, Jung CH, Lee SR, Bae JH, Baek WK, Suh MH, Park J, Park CW, Suh SI: The green tea polyphenol (-)-epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons. Life Sci 2001; 70:603-614
117. Mandel S, Weinreb O, Amit T, Youdim MB: Cell signaling pathways in the neuroprotective actions of the green tea polyphenols (-)-epigallocatechin-3- gallate: Implications for neurodegenerative diseases. J Neurochem 2004; 88:1555-1569
118. Levites Y, Youdim MB, Maor G, Mandel S: Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. Biochem Pharmacol 2002; 63:21-29
119. Chyu KY, Babbidge SM, Zhao X, Dandillaya R, Rietveld AG, Yano J, Dimayuga P, Cercek B, Shah PK: Differential effects of green tea-derived catechin on developing versus established atherosclerosis in apolipoprotein E-null mice. Circulation 2004; 109:2448-2453
120. Xiao XQ, Zhang HY, Tang XC: Huperzine A attenuates amyloid beta-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J Neurosci Res 2002; 67:30-36
121. Zhang HY, Liang YQ, Tang XC, He XC, Bai DL: Stereoselectivities of enantiomers of huperzine A in protection against beta-amyloid(25-35)-induced injury in PC12 and NG108-15 cells and cholinesterase inhibition in mice. Neurosci Lett 2002; 3:143-146
122. Xiao XQ, Yang JW, Tang XC: Huperzine A protects rat pheochromocytoma cells against hydrogen peroxide-induced injury. Neurosci Lett 1999; 275:73-76
123. Wang LM, Han YF, Tang XC: Huperzine A improves cognitive deficits caused by chronic cerebral hypoperfusion in rats. Eur J Pharmacol 2000; 398:65-72
124. Wang R, Zhang HY, Tang XC: Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta-amyloid protein-(1-40) in rat. Eur J Pharmacol 2001; 421:149-156
125. Gordon RK, Nigam SV, Weitz JA, Dave JR, Doctor BP, Ved HS: The NMDA receptor ion channel: A site for binding of Huperzine A. J Appl Toxicol 2001; Suppl 1:S47-51
126. Ye JW, Cai JX, Wang LM, Tang XC: Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment. J Pharmacol Exp Ther 1999; 288:814-819
127. Bai DL, Tang XC, He XC: Huperzine A, a potential therapeutic agent for treatment of AD. Curr Med Chem 2000; 7:355-374
128. Xu SS, Cai ZY, Qu ZW, Yang RM, Cai YL, Wang GQ, Su XQ, Zhong XS, Cheng RY, Xu WA, Li JX, Feng B: Huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Zhongguo Yao Li Xue Bao 1999; 6:486-490
129. Zhang Z, Wang X, Chen Q, Shu L, Wang J, Shan G: Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Zhonghua Yi Xue Za Zhi 2002; 82:941-944
130. Chen G, Huo Y, Tan DX, Liang Z, Zhang W, Zhang Y: Melatonin in Chinese medicinal herbs. Life Sci 2003; 73:19-26
131. Savaskan E, Olivieri G, Brydon L, Jockers R, Krauchi K, Wirz-Justice A, Muller-Spahn F: Cerebrovascular melatonin MT1-receptor alterations in patients with AD. Neurosci Lett 2001; 308:9-12
132. Wu YH, Feenstra MG, Zhou JN, Liu RY, Torano JS, Van Kan HJ, Fischer DF, Ravid R, Swaab DF: Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease; alterations in preclinical and clinical stages. J Clin Endocrinol Metab 2003; 88:5898-5906
133. Pappolla MA, Chyan YJ, Poeggeler B, Frangione B, Wilson G, Ghiso J, Reiter RJ: An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: Implications for AD. J Neural Transm 2000; 107:203-231
134. Lezoualc'h F, Sparapani M, Behl C: N-acetyl-serotonin (normelatonin) and melatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF-kappaB. J Pineal Res 1998; 24:168-178
135. Leon J, Acuna-Castroviejo D, Sainz RM, Mayo JC, Tan DX, Reiter RJ: Melatonin and mitochondrial function. Life Sci 2004; 75:765-790
136. Reiter RJ, Tan DX, Gitto E, Sainz RM, Mayo JC, Leon J, Manchester LC, Vijayalaxmi Kilic E, Kilic U: Pharmacological utility of melatonin in reducing oxidative cellular and molecular damage. Pol J Pharmacol 2004; 56:159-170
137. Montilla-Lopez P, Munoz-Agueda MC, Feijoo Lopez M, Munoz-Castaneda JR, Bujalance-Arenas I, Tunez-Finana I: Comparison of melatonin versus vitamin C on oxidative stress and antioxidant enzyme activity in AD induced by okadaic acid in neuroblastoma cells. Eur J Pharmacol 2002; 451:237-243
138. Esparza JL, Gomez M, Romeu M, Mulero M, Sanchez DJ, Mallol J, Domingo JL: Aluminum-induced pro-oxidant effects in rats: Protective role of exogenous melatonin. J Pineal Res 2003; 35:32-39
139. Matsubara E, Bryant-Thomas T, Pacheco Quinto J, Henry TL, Poeggeler B, Herbert D, Cruz-Sanchez F, Chyan YJ, Smith MA, Perry G, Shoji M, Abe K, Leone A, Grundke-Ikbal I, Wilson GL, Ghiso J, Williams C, Refolo LM, Pappolla MA, Chain DG, Neria E: Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of AD. J Neurochem 2003; 85:1101-1108
140. Lahiri DK, Chen D, Ge YW, Bondy SC, Sharman EH: Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex. J Pineal Res 2004; 36:224-231
141. Ozcankaya R, Delibas N: Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: Cross-sectional study. Croat Med J 2002; 43:28-32
142. Raghavendra V, Kulkarni SK: Possible antioxidant mechanism in melatonin reversal of aging and chronic ethanol-induced amnesia in plus-maze and passive avoidance memory tasks. Free Radic Biol Med 2001; 30:595-602
143. Maurizi CP: AD: Roles for mitochondrial damage, the hydroxyl radical, and cerebrospinal fluid deficiency of melatonin. Med Hypotheses 2001; 57:156-160
144. Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, Thomas R, Thal LJ: AD Cooperative Study. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in AD. Sleep 2003; 26:893-901
145. Kumar AM, Tims F, Cruess DG, Mintzer MJ, Ironson G, Loewenstein D, Cattan R, Fernandez JB, Eisdorfer C, Kumar M: Music therapy increases serum melatonin levels in patients with AD. Altern Ther Health Med 1999; 5:49-57
146. Srinivasan V: Melatonin oxidative stress and neurodegenerative diseases. Indian J Exp Biol 2002; 40:668-679
147. Dugo G, Salvo F, Dugo P, La Torre GL, Mondello L: Antioxidants in Sicilian wines: Analytic and compositive aspects. Drugs Exp Clin Res 2003; 29:189-202
148. Jang JH, Surh YJ: Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radic Biol Med 2003; 34:1100-1110
149. Sun AY, Draczynska-Lusiak B, Sun GY: Oxidized lipoproteins, beta amyloid peptides and AD. Neurotox Res 2001; 3:167-178
150. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M: Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: Implications for the prevention and therapeutics of AD. J Neurochem 2003; 87:172-181
151. Bastianetto S, Zheng WH, Quirion R: Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons. Br J Pharmacol 2000; 131:711-720
152. Savaskan E, Olivieri G, Meier F, Seifritz E, Wirz-Justice A, Muller-Spahn F: Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity. Gerontology 2003; 49:380-383
153. Sharma M, Gupta YK: Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci 2002; 71:2489-2498
154. Martin A, Youdim K, Szprengiel A, Shukitt-Hale B, Joseph J: Roles of vitamins E and C on neurodegenerative diseases and cognitive performance. Nutr Rev 2002; 60:308-326
155. Quinn JF, Montine KS, Moore M, Morrow JD, Kaye JA, Montine TJ: Suppression of longitudinal increase in CSF F2-isoprostanes in AD. J Alzheimers Dis 2004; 6:93-97
156. Tappel A, Tappel A: Oxidant free radical initiated chain polymerization of protein and other biomolecules and its relationship to diseases. Med Hypotheses 2004; 63:98-99
157. Fiebich BL, Lieb K, Kammerer N, Hull M: Synergistic inhibitory effect of ascorbic acid and acetylsalicylic acid on prostaglandin E2 release in primary rat microglia. J Neurochem 2003; 86:173-178
158. Yallampalli S, Micci MA, Taglialatela G: Ascorbic acid prevents beta-amyloid-induced intracellular calcium increase and cell death in PC12 cells. Neurosci Lett 1998; 251:105-108
159. Parle M, Dhingra D: Ascorbic Acid: A promising memory-enhancer in mice. J Pharmacol Sci 2003; 93:129-135
160. Quinn J, Suh J, Moore MM, Kay J, Frei B: Antioxidants in AD-vitamin C delivery to a demanding brain. J Alzheimers Dis 2003; 5:309-313
161. Riviere S, Birlouez-Aragon I, Nourhashemi F, Vellas B: Low plasma vitamin C in Alzheimer patients despite an adequate diet. Int J Geriatr Psychiatry 1998; 13:749-754
162. Charlton KE, Rabinowitz TL, Geffen LN, Dhansay MA: Lowered plasma vitamin C, but not vitamin E, concentrations in dementia patients. J Nutr Health Aging 2004; 8:99-107
163. Bourdel-Marchasson I, Delmas-Beauvieux MC, Peuchant E, Richard-Harston S, Decamps A, Reignier B, Emeriau JP, Rainfray M: Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 2001; 30:235-241
164. Paraskevas GP, Kapaki E, Libitaki G, Zournas C, Segditsa I, Papageorgiou C: Ascorbate in healthy subjects, amyotrophic lateral sclerosis and AD. Acta Neurol Scand 1997; 96:88-90
165. Kontush A, Mann U, Arlt S, Ujeyl A, Luhrs C, Muller-Thomsen T, Beisiegel U: Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with AD. Free Radic Biol Med 2001; 31:345-354
166. Morris MC, Beckett LA, Scherr PA, Hebert LE, Bennett DA, Field TS, Evans DA: Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 1998; 12:121-126
167. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC: Cache County Study Group. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study. Arch Neurol 2004; 61:82-88
168. Polidori MC, Mecocci P, Levine M, Frei B: Short-term and long-term vitamin C supplementation in humans dose-dependently increases the resistance of plasma to ex vivo lipid peroxidation. Arch Biochem Biophys 2004; 423:109-115
169. Hensley K, Benaksas EJ, Bolli R, Comp P, Grammas P, Hamdheydari L, Mou S, Pye QN, Stoddard MF, Wallis G, Williamson KS, West M, Wechter WJ, Floyd RA: New perspectives on vitamin E: Gamma-tocopherol and carboxyelthylhydroxychroman metabolites in biology and medicine. Free Radic Biol Med 2004; 36:1-15
170. Choi J, Conrad CC, Dai R, Malakowsky CA, Talent JM, Carroll CA, Weintraub ST, Gracy RW: Vitamin E prevents oxidation of antiapoptotic proteins in neuronal cells. Proteomics 2003; 3:73-77
171. Yatin SM, Varadarajan S, Butterfield DA: Vitamin E prevents Alzheimer's amyloid beta-peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production. J Alzheimers Dis 2000; 2:123-131
172. Sung S, Yao Y, Uryr K, Yang H, Lee VM, Trojanowski JQ, Pratico D: Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amlyoid deposition in a transgenic model of AD. FASEB J 2004; 18:323-325
173. Helmer C, Peuchant E, Letenneur L, Bourdel-Marchasson I, Larrieu S, Dartigues JF, Dubourg L, Thomas MJ, Barberger-Gateau P: Association between antioxidant nutritional indicators and the incidence of dementia: Results from the PAQUID prospective cohort study. Eur J Clin Nutr 2003; 57:1555-1561
174. Tabet N, Birks J, Grimley Evans J: Vitamin E for AD. Cochrane Database Syst Rev 2000; CD002854
175. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC: Cache County Study Group: Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study. Arch Neurol 2004; 61:82-88
176. Auddy B, Ferreira M, Blasina F, Lafon L, Arredondo F, Dajas F, Tripathi PC, Seal T, Mukherjee B: Screening of antioxidant activity of three Indian medicinal plants, traditionally used for the management of neurodegenerative diseases. J Ethnopharmacol 2003; 84:131-138
177. Tang SY, Whiteman M, Peng ZF, Jenner A, Yong EL, Halliwell B: Characterization of antioxidant and antiglycation properties and isolation of active ingredients from traditional Chinese medicines. Free Radic Biol Med 2004; 36:1575-1587
178. Arai H, Suzuki T, Sasaki H, Hanawa T, Toriizuka K, Yamada H: A new interventional strategy for AD by Japanese herbal medicine. Nippon Ronen Igakkai Zasshi 2000; 37:212-215
179. Kedar NP: Can we prevent Parkinson's and AD?. J Postgrad Med 2003; 49:236-245
180. Solfrizzi V, Panza F, Capurso A: The role of diet in cognitive decline. J Neural Transm 2003; 110:95-110
181. Veurink G, Liu D, Taddei K, Perry G, Smith MA, Robertson TA, Hone E, Groth DM, Atwood CS, Martins RN: Reduction of inclusion body pathology in ApoE-deficient mice fed a combination of antioxidants. Free Radic Biol Med 2003; 34:1070-1077
182. Saver JL, Kalafut M: Combination therapies and the theoretical limits of evidence-based medicine. Neuroepidemiology 2001; 20:57-64
183. Fratiglioni L, Paillard-Borg S, Winblad B: An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 2004; 3:343-353
184. Verghese J, Lipton RB, Katz MJ, Hall CB, Derby CA, Kuslansky G, Ambrose AF, Sliwinski M, Buschke H: Leisure activities and the risk of dementia in the elderly. N Engl J Med 2003; 348:2508-2516
185. Youssef FF, Addae JI: Learning may provide neuroprotection against dementia. West Indian Med J 2002; 51:143-147
186. Polidori MC: Antioxidant micronutrients in the prevention of age-related diseases. J Postgrad Med 2003; 49:229-235
187. CDC's National Center for Chronic Disease Prevention and Health Promotion website: accessed on 9-23-04 http://apps.nccd.cdc.gov/5ADaySurveillance/ displayChartV.asp?state=US&group=0